An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). (May 2020)

• Record Type: Journal Article
• Authors: D'Angelo, Alberto; Bagby, Stefan; Di Pierro, Giulia; Chirra, Martina; Nobili, Stefania; Mini, Enrico; Villari, Donata; Roviello, Giandomenico
• Is Part Of: Critical reviews in oncology/hematology. Volume 149(2020)
• Publication Date: 2020-05
• Subjects: Cabozantinib -- Non-clear renal cell carcinoma -- Efficacy -- Toxicity -- Tyrosine kinase receptor inhibitor -- Renal carcinoma -- Vascular endothelial growth factor receptor; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2020.102921
• Languages: English
• ISSNs: 1040-8428

Abstract

Graphical abstract: Abstract: Patients diagnosed with non-clear renal cell carcinoma have often been excluded from clinical trials due to the shortage of treatments available, the low incidence of tumours with non-clear histology, and the corresponding diversity of intrinsic molecular features. This approach led to a knowledge gap in finding the optimal treatment for patients diagnosed with non-clear cell renal carcinoma. Cabozantinib, a potent multiple tyrosine kinase receptor inhibitor, has been recently investigated in patients with non-clear cell histologies of renal cell cancer. In this review, we have summarized available data on the use of cabozantinib in non-clear renal cell carcinoma.